Targeted Therapies in Type II Endometrial Cancers: Too Little, but Not Too Late

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
endometrial carcinoma 5 endocrinologydiseases
everolimus 2 endocrinologydiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.


Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
everolimus 22322 inhibitors (Figure 1) [[100]]. Initially, clinical trials mainly tested derivatives from rapamycin (e.g., everolimus , temsirolimus), single mTOR kinase inhibitors primarily targeting the mTORC1 complex, in unstratified
everolimus 48728 levels using pharmacologic kinase inhibitors. However, single agent inhibitors targeting mTORC1 (e.g., everolimus ) will deactivate the negative feedback loops from p70S6K to mTORC2 and PI3K. The use of a dual PI3K/mTOR
Select Disease Character Offset Disease Term Instance
endometrial carcinoma 482 Leuven, BelgiumPublication date (epub): 8/2018Publication date (collection): 8/2018AbstractType II endometrial carcinoma s (ECs) are responsible for most endometrial cancer-related deaths due to their aggressive nature, late
endometrial carcinoma 3649 more recently also come into the limelight as potential targets in cancer, particularly in type II endometrial carcinoma s, where the tumour suppressive phosphatase protein phosphatase type 2A (PP2A) is frequently mutated.
endometrial carcinoma 4248 DiagnosisMost endometrial cancers (97%) are epithelial lesions arising from the lining of the uterus, known as endometrial carcinoma s (ECs) [[2]]. In 1983, Bokhman classified ECs into two types, based on the histopathology of the tumour
endometrial carcinoma 9404 Cancer Genome Atlas (TCGA). Initially, they analysed 3281 tumours from twelve cancer types, among which endometrial carcinoma [[33]]. TCGA objectively classified endometrial tumours based on their molecular profiles, revealing
endometrial carcinoma 51836 activator of PP2A.ijms-19-02380-t001_Table 1Table 1Most common genetic alterations in type I and type II endometrial carcinoma s (EC). Percentages in the header refer to all EC cases; percentages in the table refer to each EC subtype.Common

You must be authorized to submit a review.